Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Mural Oncology to Participate in Two Upcoming Investor Conferences
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)